Outcomes
anaemia, diarrhoea, death, fever, vomiting, cough, iron-deficiency anaemia, disability
ANAEMIA, ADVERSE EVENTS, ADVERSE EVENT, SECONDARY, IRON-DEFICIENCY ANAEMIA, IRON DEFICIENCY
The primary endpoint was haemoglobin concentration at day 84 among children in the two screen-and-treat groups versus those in the control group. A secondary aim was to compare haemoglobin concentration among children in the 12 mg screen-and-treat group with those in the 6 mg screen-and-treat group. Secondary endpoints were the proportion of participants with anaemia, iron deficiency, and iron-deficiency anaemia at day 84, the total amount of iron administered over the 12-week study period, morbidity as assessed by twice weekly questionnaires and reporting of adverse events, and safety as assessed by the ex-vivo growth of The total dosage of iron was calculated according to the fieldworker record of consumption, multiplied by the iron dose of the respective day, and summed over the whole study period. Episodes of fever, diarrhoea, vomiting, and cough were summed over the 12-week study period for each condition if the caregiver indicated that the child had developed the condition since the previous visit. Adverse events were defined as any untoward or unfavourable medical occurrence, whether considered related to the child's participation in the study or not. Serious adverse events were always investigated by the trial clinician and were defined as adverse events that were life-threatening, resulted in death, required or extended hospitalisation, or resulted in a persistent and significant disability or incapacity.